Arrowhead Pharmaceuticals shares surge 13.04% after-hours on FDA Breakthrough Therapy designation for plozasiran in severe hypertriglyceridemia.

Arrowhead Pharmaceuticals surged 13.04% in after-hours trading, driven by the FDA granting Breakthrough Therapy designation for plozasiran, targeting severe hypertriglyceridemia. This milestone accelerates regulatory timelines and underscores the drug’s potential to address a high-unmet-need market. Additional catalysts included a milestone payment from Sarepta for RNA therapy progress in myotonic dystrophy and robust financial results, including a $829.4M revenue increase and $30.1M net profit. Collaborations with Novartis and advancing clinical trials further reinforced growth prospects. While insider sales were noted, the stock’s sharp rise primarily reflected optimism around regulatory advancements and therapeutic innovation.